Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 11/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.62 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13060384 | 1.00 | KIF11 (0.62) | KIF11KCNH2CA4LTA4HLMNA | |
| SCHEMBL15212173 | 0.85 | KIF11 (0.68) | KIF11KCNH2CA4LTA4HLMNA | |
| SCHEMBL28076975 | 0.85 | KIF11 (0.54) | KIF11KCNH2CA4LTA4HLMNA | |
| SCHEMBL28076974 | 0.85 | KIF11 (0.54) | KIF11KCNH2CA4LTA4HLMNA | |
| SCHEMBL8212109 | 0.83 | MAPT (0.47) | KIF11KCNH2LTA4HLMNAHTT | |
| SCHEMBL1971090 | 0.82 | KCNN4 (0.48) | KIF11SMN1; SMN2 | |
| SCHEMBL8592606 | 0.82 | KIF11 (0.60) | KIF11KCNH2CA4LTA4HLMNA | |
| SCHEMBL17964412 | 0.82 | KIF11 (0.70) | KIF11KCNH2CA4LTA4HLMNA | |
| SCHEMBL5838167 | 0.82 | KIF11 (0.60) | KIF11KCNH2CA4LTA4HLMNA | |
| SCHEMBL9694723 | 0.82 | KIF11 (0.60) | KIF11KCNH2CA4LTA4HLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021497-B2 | Compositions and methods for synthesis of phosphorylated molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200239500-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-07-30 | — | — | US | disclosed |
| US-20200031861-A1 | BICONJUGATABLE LABELS AND METHODS OF USE | Quantum-Si Incorporated (US) | 2020-01-30 | — | — | US | disclosed |
| WO-2017165851-A1 | PROCESS FOR THE PREPARATION OF PEGYLATED DRUG-LINKERS AND INTERMEDIATES THEREOF | SEATTLE GENETICS, INC. (US) | 2017-09-28 | — | — | WO | disclosed |
| EP-1917020-B1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS INC (US) | 2016-05-25 | — | — | EP | disclosed |
| US-20160089446-A1 | Modified Hydrogels | ASCENDIS PHARMA A/S (DK) | 2016-03-31 | — | — | US | disclosed |
| EP-2489364-B1 | Monomethylvaline compounds conjugated to antibodies | SEATTLE GENETICS INC (US) | 2015-01-07 | — | — | EP | disclosed |
| US-8557780-B2 | Monomethylvaline compounds capable of conjugation to ligands | SEATTLE GENETICS, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20130064843-A1 | Identification of conserved peptide blocks in homologous polypeptides | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-20120289457-A1 | PEPTIDE OLIGONUCLEOTIDE CONJUGATES | AVI BIOPHARMA, INC. (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120238740-A1 | NON-POLAR AND POLAR LEAVING GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-09-20 | — | — | US | disclosed |
| US-20120065169-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2012-03-15 | — | — | US | disclosed |
| US-20120034247-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-20120027784-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120027783-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-7446186-B2 | Pyrroles substituted by oligonucleotides | BIOMERIEUX (FR) | 2008-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031861-A1 | BICONJUGATABLE LABELS AND METHODS OF USE | CLTB, HLCS, CD44 | KIF11 1572/4885KCNH2 4852/4885CA4 2567/4885 |
| US-20120238740-A1 | NON-POLAR AND POLAR LEAVING GROUPS | PGLS, RABGGTB, LNPEP | KIF11 505/4885KCNH2 1152/4885CA4 3681/4885 |
| US-20160089446-A1 | Modified Hydrogels | CD44, DNPH1, PHYKPL | KIF11 4228/4885KCNH2 4389/4885CA4 1385/4885 |
| US-20200239500-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | PIK3CA, CHAMP1, TYMP | KIF11 2519/4885KCNH2 3514/4885CA4 2075/4885 |
| US-20120065169-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | NSUN2, UPF1, RTCB | KIF11 2391/4885KCNH2 4825/4885CA4 4692/4885 |
| US-20120027783-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | MMAB, CAD, VIM | KIF11 3035/4885KCNH2 4238/4885CA4 3198/4885 |
| US-20120027784-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | MMAB, CAD, VIM | KIF11 3035/4885KCNH2 4238/4885CA4 3198/4885 |
| US-20120034247-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | MMAB, CAD, VIM | KIF11 3035/4885KCNH2 4238/4885CA4 3198/4885 |
| US-11021497-B2 | Compositions and methods for synthesis of phosphorylated molecules | PIK3CA, CHAMP1, TYMP | KIF11 2519/4885KCNH2 3514/4885CA4 2075/4885 |
| US-20120289457-A1 | PEPTIDE OLIGONUCLEOTIDE CONJUGATES | SNRPE, SMN1; SMN2, UPF1 | KIF11 2968/4885KCNH2 4863/4885CA4 4654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.